Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials.

@article{Jackman2009ImpactOE,
  title={Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials.},
  author={David Michael Jackman and Vincent A. Miller and L Cioffredi and Beow Yong Yeap and Pasi Antero J{\"a}nne and Gregory J Riely and Marielle Gallegos Ruiz and Guiseppe Giaccone and Lecia V Sequist and Bruce Evan Johnson},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2009},
  volume={15 16},
  pages={5267-73}
}
PURPOSE The impact of epidermal growth factor receptor (EGFR) and KRAS genotypes on outcomes with erlotinib or gefitinib therapy continues to be debated. This study combines patient data from five trials in predominantly Western populations to assess the impact of EGFR and KRAS mutations on first-line therapy with an EGFR-tyrosine kinase inhibitor (TKI) and compare clinical versus molecular predictors of sensitivity. EXPERIMENTAL DESIGN Chemotherapy-naïve patients with advanced non-small cell… CONTINUE READING
Highly Influential
This paper has highly influenced 10 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS
164 Citations
26 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 164 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 26 references

Frequen - cy and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma

  • KrisMG RielyGJ, RosenbaumD
  • Clin Cancer Res
  • 2008

Phase II study of erlotinib in chemo - naive women with advanced pulmonary adenocarcinoma

  • DM Jackman, N Lindeman, J Lucca
  • J Clin Oncol
  • 2007

Similar Papers

Loading similar papers…